Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/26/2020 11:07 PDT] Aptevo Therapeutics Inc. (NASDAQ:APVO), Up By 100.00% ($6.17) From $6.170 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/22/2020 07:38 PDT] APVO Expected to Trade Up Short Term
• [05/11/2020 11:07 PDT] Aptevo Therapeutics Inc. (NASDAQ:APVO), Up By 100.00% ($6.42) From $6.420 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/11/2020 08:05 PDT] APVO Expected to Trade Up Short Term
• [04/17/2020 08:04 PDT] APVO Expected to Trade Down After Bearish Patterns Develop
• [04/03/2020 13:01 PDT] Aptevo Therapeutics Inc. (NASDAQ:APVO), Down By 100.00% ($4.05) From $4.050 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions